43 results about "Cell penetration" patented technology

The application discloses a stapled peptide compound for selectively degrading MYC protein, a preparation method and application thereof; the compound is sequentially connected in the N-terminal to C-terminal direction by a peptide recognition segment, a flexible linker and a chaperone-mediated autophagy recognition motif KFERQ or a similar motif; the peptide recognition segment is introduced by an (i, i+7) site alkenyl amino acid and a Grubbs catalytic RCM reaction to form a full carbon hydrogen stapling bridge to stabilize the alpha-helix conformation; stapled modification of a typical compound MAX-7 significantly improves the alpha-helix content, the protease stability and the cell penetration, so that the compound can efficiently enter cells and be located in lysosomes, and MYC protein is selectively degraded through the CMA pathway; in-vitro experiments show that MAX-7 can inhibit the proliferation, migration and invasion of various MYC-driven tumor cells, and induce apoptosis; the application provides a brand-new lysosome-directed degradation strategy for the "undruggable" target MYC, and establishes a universal technical platform which can be popularized to other difficult drug proteins.

The invention provides a p53 fusion protein based on a targeted colorectal cancer marker CEA and application of the p53 fusion protein in preparation of medicines for inhibiting colorectal cancer, and relates to the field of biological medicines. The fusion protein comprises any one of the following components: p28-p53, MBP-TEV-p14ARF (1-63)-linker-p28, p28-p53-CEABP1, CEABP1-p28-p53, and CEABP2-p28-p53, and the fusion protein comprises any one component selected from the group consisting of the following components: a protein A, a protein B, a protein A, a protein B, a protein C and a protein B, according to the application, p53 and p14 ARF proteins for inhibiting cell proliferation in a human body, cell-penetrating peptide and designed protein CEABP1 or CEABP2 of a targeted binding colorectal cancer marker CEA are fused for the first time, and cell experiments and mouse experiments prove that the protein has a relatively high function of inhibiting growth of colorectal cancer cells, does not influence normal cell growth and has a wide application value.

The present application relates to the technical field of genetic engineering, and specifically discloses a Chlamydomonas reinhardtii SnRK2.7 gene and application thereof in adaptation to osmotic stress and maintenance of cell survival. The present application first discloses SnRK2.7 the key biological function of the gene in maintaining Chlamydomonas cell homeostasis. By knocking out the gene through CRISPR / Cas9 gene editing technology and adopting an expression frame driven by an endogenous promoter for genetic back complementation, it is confirmed that SnRK2.7 the gene positively regulates cell osmotic stress tolerance and maintains cell long-term survival. In addition, the present application first discovers that the SnRK2.7 protein is specifically located in the Chlamydomonas expansion vesicle, which provides direct spatial evidence for the cell function. The above discovery not only expands the understanding of the osmotic stress signal transduction mechanism of Chlamydomonas, but also provides a new gene target and research tool for the improvement of microalgae stress adaptability, and has important basic research value and biological technology application potential.

The utility model discloses a brine blending device for a red blood cell osmotic brittleness test. The brine blending device comprises a main shell and a position mark sensing unit, a salt water blending unit and a center alignment unit; a master controller; a to-be-loaded test tube group is placed on the bottom placing table, the center alignment unit is used for placing the to-be-loaded test tube group in the middle position, the position mark sensing unit is used for measuring and calculating the distance between the head test tube and the tail test tube of the test tube group so as to guide the horizontal moving unit to rapidly move to the position over the test tubes relative to the center of the device, and the visual camera and the injection angle adjusting assembly are used for adjusting the injection angle. The injection head is aligned with a test tube opening, and the metering pump is started to inject saline water and distilled water into the test tube according to a fixed proportion. Based on a saline water filling mode of mobile hovering injection, a horizontal moving unit is arranged to realize movement of an injection head above a test tube group, so that the problem of material resource waste caused by a traditional one-tube one-path scheme is solved; in addition, by arranging a visual camera and an ejection angle adjusting assembly, the technical risk that saline water is injected out of the test tube is avoided to a great extent.

The application belongs to the technical field of biological medicine, and particularly relates to a cell penetration inhibitory peptide and application thereof in breast cancer. Specifically, aiming at the interaction between circHIF-1alpha (11, 12) and IGF2BP2, a novel compound named cell penetration IGF2BP2 inhibitory peptide (IIP) is designed to intervene, so as to inhibit the energy metabolism re-regulation and tumor progression of breast cancer. The application first discloses a new use of IIP as an inhibitor of circHIF-1alpha (11, 12). In-vitro experiments prove that IIP can significantly inhibit the energy metabolism reprogramming and tumor progression of breast cancer cells. In summary, the application provides an innovative breast cancer treatment method based on the interaction between circRNA and protein, and successfully intervenes the disease process of breast cancer through the design and application of IIP, which opens up a new direction and possibility for the development of breast cancer treatment.

The invention discloses a CD3 antibody-polypeptide, which is characterized in that an amino acid sequence of a light chain variable region of a CD3 antibody is linked with an amino acid sequence of polypeptide through a triple link of a GGGGS flexible joint; and the CD3 antibody-polypeptide can be coupled with the RNP compound through a chemical bond to form the CD3 antibody-polypeptide-RNP compound. The CD3 antibody-polypeptide-RNP compound is used as a delivery system for gene editing in the TILs cells, in the gene editing process, CD3 antibody-polypeptide has good cell penetrability and stability, an exogenous gene can be efficiently and accurately delivered into a double-chain incision manufactured on a TRAC gene of the TILs cells, cell damage caused by electrotransfection is avoided, and the CD3 antibody-polypeptide-RNP compound can be applied to gene editing of the TILs cells. The prepared TI Ls cells have a higher proportion of memory T cells (CD45RO < + > CD62L < + >) and a higher proportion of tumor specific T cells (CD8 < + >), so that the TI Ls cells have a better tumor killing effect.

The present application relates to a kind of new cell penetrating peptides and its use. It is proved that the 12 cell penetrating peptides of the present application have excellent cell penetration ability and mass transfer effect in vitro and in vivo, since the above-mentioned cell penetrating peptides can effectively deliver biologically active substances to cells, tissues and other in vivo, and are expected to be widely used in research fields, various disease diagnosis and treatment fields, etc.

Described is an antibody-drug conjugate (ADC) having the formula A-L, wherein A is an antibody or an antibody fragment and wherein L is a linker, said linker comprising: as a first payload a topoisomerase I inhibitor which is cell-permeable, preferably a camptothecin cytotoxic molecule which is cell-permeable; and as a second payload a topoisomerase I inhibitor which is not cell-permeable, preferably a camptothecin cytotoxic molecule which is not cell-permeable. Moreover, described is a pharmaceutical composition comprising said ADC and at least one pharmaceutically acceptable ingredient. Further, described is an ADC for use in a method of treating a patient suffering from, being at risk of developing, and / or being diagnosed for a neoplastic disease.

The invention belongs to the technical field of traditional Chinese medicine extraction, and particularly relates to an extraction method of a high-activity ginseng extract, which is used for improving the conversion and extraction efficiency of rare ginsenoside Rg1, Rg3, Rg5, Rh2 and Compound K. The extraction method combines microbial fermentation, electrostatic field wall breaking and supercritical CO2 extraction, the high-voltage pulse electric field induces ginseng cells to generate an electroporation effect, permeability of cell membranes and cell walls is improved, supercritical CO2 extraction has high cell permeability, the extraction rate and purity of ginsenoside are improved, and in addition, a catalytic promoter added in the extraction process is beneficial to conversion catalysis of rare ginsenoside components.

The invention belongs to the technical field of traditional Chinese medicine preparations, and particularly relates to an osteoarthritis targeted traditional Chinese medicine nano preparation and a preparation method thereof.The traditional Chinese medicine nano preparation is prepared from, by weight, 15-25 parts of traditional Chinese medicine extract, 4-8 parts of functional peptide, 3 parts of nano zinc oxide, 12-15 parts of coupling agent, 10 parts of modifier, 30-48 parts of phospholipid and 14 parts of cholesterol; the traditional Chinese medicine extract obtained through toxicity attenuation and purification contains rich terpenoids, flavones, saponins and other micromolecular anti-inflammatory immune regulation active substances, multi-target treatment of arthritis is provided, the designed functional polypeptide has inflammation specific response and cell penetrating capacity, focus enrichment of treatment components is achieved, and the treatment effect is good. The toxicity to normal tissues is reduced while the curative effect is improved.

Compounds having the structure (3) as shown in the specification wherein Y is as defined in the specification and wherein: [R2bR2a] represents a reaction product between R2b and R2a of Formulas (2) and (1), respectively, R3 functions as a cell penetration moiety, and R1 functions as a binding moiety to bind to the payload (P) to form a conjugate with P, wherein R1, R3, A, D, L1, L2, L3, L4, L5, L6, L7, r, m, s, n, p, and q are as defined in further detail elsewhere in this disclosure. Also described herein are methods of producing compounds of Formulas (1), (2), and (3), conjugates thereof with a payload (P), pharmaceutical compositions thereof, methods of delivering the conjugates to subjects or cells, and methods of treating a disease or condition by administering such conjugates.

Formulas for use in enhancing the transduction efficiency of lentiviral vector (LV) particles into various target cells are disclosed herein. For example, a formulation for use in enhancing the transduction of paramyxovirus pseudotype lentiviral vector particles into target cells may comprise a cell-permeable peptide (CPP) comprising at least one of Vectofusion-1 or LAH4-C; and poloxamer 407, wherein the concentration of poloxamer 407 is greater than or equal to the concentration of CPP. Additionally, a method of using such formulations to enhance the transduction of LV particles, including particularly in vivo transduction, is disclosed herein.

The invention discloses a polypeptide coupling compound as well as a preparation method and application thereof, and relates to the technical field of polypeptides. The structure of the polypeptide coupling compound is shown in the specification, and the Peptide is any one polypeptide sequence as shown in SEQ ID NO. 1 to 38. The resorcinol compound is coupled with the polypeptide sequence, so that the water solubility of the resorcinol derivative is remarkably improved, the cell penetrability and the skin permeability are improved, the effective transfer of the resorcinol derivative in the skin is promoted, and meanwhile, the skin beautifying effect of polypeptide and the whitening activity of the resorcinol derivative are fused; and multiple effects of whitening, wrinkle resistance and aging resistance are realized. The polypeptide coupling compound provided by the invention is simple in structure, mild in reaction condition, easy to prepare, high in synthesis success rate and relatively high in product purity, and has a good market prospect when being applied to whitening cosmetics.

The present application relates to the field of biological materials, in particular to a high-efficiency transdermal recombinant humanized elastin as well as a preparation method and application thereof. In view of the problem that macromolecular drugs and proteins are difficult to be effectively absorbed through skin in the prior art, the present application discloses a high-efficiency transdermal recombinant humanized elastin, a coding gene, a recombinant vector, a recombinant genetically engineered bacterium, and a preparation method and application thereof. The protein has cell penetration ability and transdermal ability, and is obtained by protease cleavage from a precursor elastin. The nucleotide sequence of the coding gene of the precursor elastin is a sequence shown in SEQ ID NO. 3 or an equivalent sequence. The recombinant humanized elastin of the present application can be applied to skin care products, dressings, implants, artificial skin, artificial blood vessels, medical devices, biological materials or functional foods, and is particularly suitable for external preparations for anti-wrinkle, anti-aging or skin barrier repair.

The present application belongs to the field of polypeptide drug preparation, and particularly relates to a kind of short peptide dimer and its nanocomposite.The tripeptide (Ser-Cys-Arg) is assembled to form short peptide dimer by hydrogen bond in aqueous solution, which first discloses that short peptide forms cyclic dimer structure through intermolecular hydrogen bond, without using chemical crosslinking agent, oxidizing agent or protection / deprotection step, and the process is more simple and mild, and more suitable for synergistic assembly with drug molecules to form nanocomposite.The short peptide dimer provided by the present application can efficiently encapsulate model drugs to form "peptide-drug" nanocomposite, which can diffuse in gel matrix to epidermis, form multiple non-covalent interactions with skin lipids and keratin, significantly improve the transdermal permeability of drugs through dual pathways of cell penetration and intercellular gap transport, and reach the action site to realize efficient targeted drug release.

The invention discloses application of a composite biological material in hernia repair surgery, and belongs to the technical field of biotechnology, the composite biological material comprises a nanofiber scaffold, the scaffold is prepared by compounding polylactic acid-glycolic acid and silk fibroin, the weight ratio of the polylactic acid-glycolic acid to the silk fibroin is 70: 30, and the weight ratio of the polylactic acid-glycolic acid to the silk fibroin is 20: 30. The nanofiber scaffold is prepared through an electrostatic spinning technology and is used for providing mechanical support and promoting cell attachment and proliferation; the fiber is of a porous structure, the pore size is 10-100 microns, and cell permeation and nutrient substance exchange are facilitated; the polylactic acid-glycolic acid / silk fibroin composite scaffold is prepared by compounding polylactic acid-glycolic acid and silk fibroin, the mechanical properties of natural tissues are simulated, and a good growth scaffold is provided for cells. The gel layer is prepared through a solution phase separation method, and provides additional biological activity support and a cell attachment surface for the nanofiber scaffold. By arranging the antibacterial coating, the risk of postoperative infection is reduced, and meanwhile, protection is provided for materials and human tissues.

The present application relates to the use of a composition for preventing, alleviating or treating coccidiosis and against Eimeria protozoa. The composition comprises an active ingredient for preventing, relieving or treating coccidiosis, and the active ingredient consists of coumaric acid or a pharmaceutically acceptable salt thereof. According to one embodiment, the composition comprising cumaric acid and / or a salt thereof has an excellent effect of inhibiting cell infiltration of protozoa capable of inducing coccidiosis and / or inhibiting proliferation of protozoa in cells, has an excellent effect of preventing, alleviating and treating coccidiosis in vivo, and significantly reduces the oocyst excretion rate in faeces, and thus has an excellent effect of preventing, alleviating and treating coccidiosis in vivo. Therefore, secondary coccidiosis infection can be reduced.

This invention relates to a cell-penetrating peptide Y119E and its application in inhibiting the growth of cisplatin-resistant tumors. The invention is characterized by using the cell-penetrating peptide TAT as a carrier to deliver a cell-penetrating peptide containing PGAM1 phosphorylated at position Y119 into tumor cells. The cell-penetrating peptide containing Y119 phosphorylated peptide (Y119E) has the sequence YGRKKRRQRRR-KIWRRSEDVP. The short cell-penetrating peptide Y119E is used in the drug application of inhibiting the growth of cisplatin-resistant tumors. It can effectively inhibit tumor growth subcutaneously in nude mice.

The application discloses a proteolysis body (PROTAC) targeting HIV protease and application thereof, the PROTAC is a polypeptide structure, a general formula is R1-L-E3L or R1-L-E3L-R2, wherein R1 is a target ligand of HIV protease, L is a GSGS linker, E3L is a ligand of VHL (von Hippel-Lindau) E3 ubiquitin ligase, and R2 is a D-configuration arginine cell penetration peptide; the PROTAC can recruit E3 ligase, specifically induce ubiquitination and degradation of HIV protease in a proteasome-dependent manner; the application further provides a gene encoding the PROTAC, a recombinant carrier, a pharmaceutical preparation and application of the gene in preparation of an anti-AIDS drug.

The application discloses a TAT-recombinant avian beta defensin fusion protein and a coding gene and application thereof, and belongs to the technical field of variation or genetic engineering. The application firstly fuses TAT with a recombinant avian beta defensin (AvBD) to construct a TAT-recombinant avian beta defensin fusion protein, the efficient cell penetration ability of TAT is fused with the antiviral ability of the recombinant avian beta defensin, and the inhibiting effect on virus infection is significantly enhanced. The fusion protein shows excellent antiviral activity in an in-vitro cell model and an in-vivo live chicken experiment, and can be applied as an antiviral biological preparation. The application uses a cell-penetrating peptide TAT to prepare a transmembrane delivery system, realizes intracellular delivery of a protein in one step, significantly inhibits in-vitro and in-vivo proliferation of avian viruses such as ALV-J, REV, MDV, CIAV and the like, is safe and efficient, can be developed into a broad-spectrum antiviral biological preparation, and simultaneously creates a new idea for research on prevention and treatment of avian viruses.

The application provides a gH625-H2A histone and chromatin and application thereof, the histone is that a peptide gH625 is added into histone H2A; the application comprises application of the gH625-H2A histone and chromatin in preparation of a drug or a drug delivery system and application of the gH625-H2A histone and chromatin in preparation of skin care products and cosmetics; the application provides the gH625-H2A histone and chromatin; the histone and the chromatin have strong cell penetration and skin penetration effect; the histone and the chromatin are expected to promote development of a transdermal gene delivery system and biological drugs and skin care products; the biological drugs and the skin care products prepared by the application do not need physical or chemical intervention, and passive skin delivery of nucleic acids, small peptides, growth factors and enzymes is realized.

The present invention relates to a cell-permeable peptide comprising the amino acid sequence of SEQ ID NO. 1.

The invention discloses an MYH2-FIGN interaction blocking amino acid compound and application thereof, and relates to the field of polypeptide drugs and tumor prevention and treatment. The MYH2-FIGN interaction blocking amino acid compound is an amino acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 3 or a polypeptide derivative of the amino acid sequence. The invention also discloses a pharmaceutical composition, which comprises the MYH2-FIGN interaction blocking amino acid compound and a pharmaceutically acceptable carrier. The polypeptide drug targeting the MYH2-FIGN interaction interface is designed for the first time, compared with traditional small molecules, the polypeptide drug has specificity on MYH2-FIGN interaction inhibition, by means of fusion of iRGD peptide, the problem of polypeptide cell penetration is solved, tumor targeting is given to the polypeptide drug, the bioavailability of the drug is improved, systematic toxicity is reduced, and the polypeptide drug has good application prospects. The polypeptide medicine can adopt various medicine dosage forms, and the preparation process is simple.

The present invention concerns fusion polypeptides comprising a cell penetration and a substrate binding domain. Additionally, the present invention concerns a genetically modified cell expressing these fusion polypeptides as well as the use of these fusion polypeptides for introducing a substance into a target cell.

The invention discloses application of TAT-MSI1 fusion protein in promotion of virus in-vitro proliferation, and belongs to the technical field of virology. The TAT and the RNA binding protein MSI1 are fused for the first time, the TAT-MSI1 fusion protein is constructed, the efficient cell penetrating power of the TAT is combined with the RNA binding protein function of the MSI1, and a brand new tool is provided for studying replication of some viruses difficult to replication; secondly, a transmembrane delivery system is prepared by using the cell-penetrating peptide TAT, so that a technical means is provided for rapidly and greatly obtaining antigens in vaccine production.

The present application belongs to the technical field of traditional Chinese medicine extraction, and particularly relates to an extraction method of high-activity ginseng extract, which is used for improving the conversion and extraction efficiency of rare ginsenosides Rg1, Rg3, Rg5, Rh2 and Compound K. The extraction method combines microbial fermentation, electrostatic field wall breaking and supercritical CO2 extraction. The microbial fermentation treatment is mainly used for promoting the synthesis of ginsenosides, the high-voltage pulse electric field induces the electroporation effect of ginseng cells to increase the permeability of cell membrane and cell wall, the supercritical CO2 extraction has high cell permeability to improve the extraction rate and purity of ginsenosides, and in addition, the catalytic aid added in the extraction process is helpful to the conversion and catalysis of rare ginsenoside components.

Compounds having the following structure:wherein Y=wherein: [R2bR2a] represents a reaction product between R2b and R2a of Formulas (2) and (1), respectively, R3 functions as a cell penetration moiety, and R1 functions as a binding moiety to bind to the payload (P) to form a conjugate with P, wherein R1, R3, A, D, L1, L2, L3, L4, L5, L6, L7, r, m, s, n, p, and q are as defined in further detail elsewhere in this disclosure. Also described herein are methods of producing compounds of Formulas (1), (2), and (3), conjugates thereof with a payload (P), pharmaceutical compositions thereof, methods of delivering the conjugates to subjects or cells, and methods of treating a disease or condition by administering such conjugates.

The present application relates to an anticoccidial composition comprising coumaric acid and use thereof. A composition comprising coumaric acid and / or a salt thereof, according to an embodiment, has excellent effects of inhibiting the cell penetration of protozoa that can induce coccidiosis and / or inhibiting the proliferation of the protozoa in cells, has excellent effects of preventing, ameliorating and treating coccidiosis in vivo, and remarkably reduces oocyst excretion in feces, thus being able to reduce secondary coccidiosis infection.

The present application relates to an anticoccidial composition comprising a stilbene-based compound, and a use thereof. A composition comprising a compound or a salt thereof, according to one embodiment, has excellent effects of direct killing of protozoa that can induce coccidiosis, inhibiting the cell penetration of the protozoa and / or inhibiting the intracellular proliferation of the protozoa, and preventing, alleviating, and treating in vivo coccidiosis.

The invention discloses a composite functional microsphere for repairing radiation damage and promoting collagen regeneration as well as a preparation method and application of the composite functional microsphere. The microsphere comprises a porous microsphere carrier prepared from a high polymer material with excellent biocompatibility and degradability, and repair polypeptide with functions of cell penetration, free radical removal, DNA protection and apoptosis resistance is loaded in the porous microsphere carrier or covalently bound on the surface of the porous microsphere carrier. The porous microsphere carrier disclosed by the invention is used as a long-term resident sustained-release storage cavern and a physical support bracket, can realize continuous and controllable release of polypeptide through internal pores or a surface modification layer of the microspheres, and can provide free radical scavenging and cell protection effects on an injured part for a long time; meanwhile, the stable three-dimensional space structure of the porous microsphere carrier can provide anchoring points for repairing cells such as fibroblasts and directly guide and support ordered deposition of new collagen fibers, so that substantial regeneration and reconstruction of a tissue structure are mechanically promoted while long-acting molecular protection is achieved.